P766: No difference in progression of disability 2 years after stopping infliximab or immunosuppressant vs. continuing combination therapy in patients with CD in sustained steroid-free remission: a subanalysis of SPAREECCO'24Year: 2024
Authors: Vieujean, S.(1)*;Desseaux, K.(2);Laharie, D.(3);Satsangi, J.(4);Ding, N.(5);Siegmund, B.(6);D’Haens, G.(7); Picon, L.(8);Bossuyt, P.(9);Vuitton, L.(10);Irving, P.(11);Viennot, S.(12);Lamb, C.A.(13);Pollok, R.(14);Baert, F.(15);Nachury, M.(16);Fumery, M.(17);Gilletta, C.(18);Resche-Rigon, M.(19);Bouhnik, Y.(20);Colombel, J.F.(21);Hertervig, E.(22);Louis, E.(23);
(1)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(2)Hôpital Saint-Louis, ECSTRRA - CRESS UMR1153- INSERM and SBIM- AP-HP, Paris, France;(3)Hôpital Haut-Lévêque– Université de Bordeaux, Service d’Hépatogastroentérologie et oncologie digestive CHU de Bordeaux, Bordeaux, France;(4)John Radcliffe Hospital, Translational Gastroenterology Unit- Nuffield Department of Medicine, Oxford, United Kingdom;(5)St Vincent@E@s Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(6)Universitätsmedizin Berlin, Medical Department- Division of Gastroenterology- Infectious Diseases and Rheumatology- Charité, Berlin, Germany;(7)Amsterdam University Medical Centres, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)Hôpital Trousseau, Hépato-Gastro-Onco-Entérologie, Tours, France;(9)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(10)Besançon Univeristy Hospital, Department of Gastroenterology-, Besançon, France;(11)Guy@E@s and St Thomas@E@ NHS Foundation Trust, IBD Unit- Department of Gastroenterology, London, United Kingdom;(12)University Hospital of Caen, Department of Gastroenterology, Caen, France;(13)Newcastle upon Tyne Hospitals NHS Foundation Trust- Royal Victoria Infirmary, Department of Gastroenterology, Newcastle upon Tyne, United Kingdom;(14)St Georges University Hospital, Gastroenterology, London, United Kingdom;(15)AZ Delta, Department of Gastroenterologie, Roeselare, Belgium;(16)University of Lille- Inserm- CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation-, Lille, France;(17)University Hospital of Amiens, Department of Gastroenterology, Amiens, France;(18)University Hospital of Toulouse Rangueil, Department of Gastroenterology and Pancreatology, Toulouse, France;(19)Hôpital SaintLouis, Université de Paris- ECSTRRA - CRESS UMR1153- INSERM and SBIM- AP-HP, Paris, France;(20)Beaujon Hospital- APHP- Paris Cité University, Department of Gastroenterology, Clichy, France;(21)Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States;(22)Skåne University Hospital, Department of Gastroenterology, Lund, Sweden;(23)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;GETAID and the SPARE-Biocycle research group
P767: Pharmacokinetics of subcutaneous infliximab induction and maintenance in patients with moderate-to-severely active Crohn’s diseaseECCO'24Year: 2024
Authors: AnjieMD, S.(1)*;Mâthot, R.A.A.(2);Gecse, K.B.(1);D@E@Haens, G.R.A.M.(1);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Department of Hospital Pharmacy and Clinical Pharmacology, Amsterdam, The Netherlands;
P768: Appropriateness of small molecule agents for patients with IBD of childbearing age – a RAND appropriateness panelECCO'24Year: 2024
Authors: Selinger, C.P.(1)*;Laube, R.(2);Fraser, A.(3);Headley, K.(4);Kent, A.(5);Kok, K.(6);Lee, V.(4);Limdi, J.(7);Ludlow, H.(8);Rees, F.(9);Sagar, N.(10);Walker, E.(4);
(1)St James@E@ University Hospital, Gastroenterology, Leeds, United Kingdom;(2)Macquarie University Hospital, Gastroenterology, Sydney, Australia;(3)University Hospitals of Bristol, Gastroenterology, Bristol, United Kingdom;(4)Patient representative, Patient representative, Leeds, United Kingdom;(5)Kings College Hospital, Gastroenterology, London, United Kingdom;(6)Barts Health NHS Trust, Gastroenterology, London, United Kingdom;(7)Northern Care Alliance, Gastroenterology, Manchester, United Kingdom;(8)University Health Board Cardiff and Vale, Gastroenterology, Cardiff, United Kingdom;(9)University Hospital Sussex NHS Trust, Gastroenterology, Brighton, United Kingdom;(10)Walsall Healthcare NHS Trust, Gastroenterology, Walsall, United Kingdom;
P769: Impact of discontinuation of anti-TNF therapy: A long term follow-up data of risks and predictors relapse in a large Indian cohortECCO'24Year: 2024
Authors: Banerjee, R.(1)*;Pal, P.(1);Mekala, D.(1);Raghunathan, N.(1);Joshi, V.(1);Akki, Y.(1);Patel, R.(1);Godbole, S.(1);Valluri, S.(1);Nagasuri, P.(1);Haridas, A.(1);
(1)Asian Institute of Gastroenterology, IBD Centre, Hyderabad, India;
P770: Proactive Infliximab monitoring improves the rates of transmural remission in Crohn’s disease – a propensity score matched analysisECCO'24Year: 2024
Authors: Fernandes, S.R.(1,2,3);Tubal Bronze, S.M.(1,2)*;Saraiva, S.(1,3);Bernardo, S.(1,3);Gonçalves, A.(1,3);Moura Santos, P.(1,2,3);Valente, A.(1);Correia, L.(1,2,3);Cortez-Pinto, H.(1,2);Magro, F.(3,4,5,6,7);
(1)Centro Hospitalar Universitário Lisboa Norte EPE, Serviço de Gastrenterologia e Hepatologia, Lisbon, Portugal;(2)Faculdade de Medicina da Universidade de Lisboa, Clinica Universitária de Gastrenterologia, Lisbon, Portugal;(3)Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii, Porto, Portugal;(4)São João Hospital University Center, Gastroenterology Department, Porto, Portugal;(5)Faculty of Medicine- University of Porto, Department of Biomedicine- Unit of Pharmacology and Therapeutics, Porto, Portugal;(6)Faculty of Medicine- University of Porto, Centre for Health Technology and Services Research- Health Research Network CINTESIS@RISE, Porto, Portugal;(7)São João Hospital University Center, Clinical Pharmacology Unit, Porto, Portugal;
P771: Comparing obstructive symptoms and dietary restrictions with Crohn@E@s disease stricture severityECCO'24Year: 2024
Authors: Saunders , B.(1);Lesack , K.(1);Rosentreter , R.(1);Macci , A.(1);Novak , K.(1);Ma , C.(1);Kaplan , G.(1);Ingram , R.J.(1);Seow , C.(1);Panaccione- , R.(1);Lu , C.(1)*;
(1)University of Calgary, Medicine- Division of Gastroenterology and Hepatology, Calgary, Canada;
P772: Comprehensive disease control in patients with Ulcerative Colitis: refinement of a multi-component endpoint using data from the filgotinib SELECTION trialECCO'24Year: 2024
Authors: Schreiber, S.W.(1)*;Feagan, B.G.(2,3);Vermeire, S.(4);Danese, S.(5,6);Vyncke, V.(7);Faes, M.(8);Oortwijn, A.(9);Peyrin-Biroulet, L.(10,11,12,13,14,15);
(1)Kiel University- University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(2)Alimentiv Inc., Senior Scientific Director, London ON, Canada;(3)Western University, Division of Gastroenterology- London Health Sciences Centre, London ON, Canada;(4)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)IRCCS Hospital San Raffaele, Department of Gastroenterology and Digestive Endoscopy, Milan, Italy;(6)Vita-Salute San Raffaele University, Department of Gastroenterology, Milan, Italy;(7)Galapagos NV, Medical Affairs, Mechelen, Belgium;(8)Galapagos NV, Biostatistics, Mechelen, Belgium;(9)Galapagos B.V., Medical Affairs, Leiden, The Netherlands;(10)Nancy University Hospital, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(11)McGill University Health Centre, Division of Gastroenterology and Hepatology, Montreal QC, Canada;(12)Paris IBD Center, Ambroise Paré – Hartmann Private Hospital Group, Neuilly-sur-Seine, France;(13)Nancy University Hospital, FHU Curing and Preventing IMID CURE, Vandœuvre-lès-Nancy, France;(14)Nancy University Hospital, INFINY Institute, Vandœuvre-lès-Nancy, France;(15)University of Lorraine, Inserm- NGERE, Nancy, France;
P774: Less combination therapy and more fistulotomy in perianal fistulizing Crohn’s disease in the elderlyECCO'24Year: 2024
Authors: Arjafallah Goulet, O.(1)*;Brochard, C.(2);Atienza, P.(1);Siproudhis, L.(2);Etienney, I.(1);
(1)GH Diaconesses Croix Saint Simon Hospital, Proctology, Paris, France;(2)CHU Pontchaillou, Gastroenterology and proctology, Rennes, France;
P775: Efficacy and safety of risankizumab in children with Crohn’s disease: A preliminary reportECCO'24Year: 2024
Authors: Spencer, E.(1);Stein, R.(2);Shalem, T.(3);Zifman, E.(4);Dubinsky, M.(5);Lev Tzion, R.(6);Turner, D.(6);Assa, A.(7)*;
(1)Mount Sinai Hospital- New York City- NY- USA., Division of Gastroenterology- Hepatology and Nutrition-, New York City- NY, United States;(2)The Children@E@s Hospital of Philadelphia- Philadelphia- PA.- USA, Division of Gastroenterology- Hepatology- and Nutrition, Philadelphia- PA, United States;(3)Shamir Assaf Harofeh Medical Center and the Faculty of Medicine- Tel Aviv University- Israel, Pediatric Gastroenterology Institute, Zeriffin, Israel;(4)Meir Medical Center- Kfar-Saba and the Faculty of Medicine- Tel Aviv University- Israel, The Pediatric Gastroenterology Unit-, Kfar-Saba, Israel;(5)Mount Sinai Hospital- New York City- NY- USA., Division of Gastroenterology- Hepatology and Nutrition, New York City- NY, United States;(6)Shaare Zedek Medical Center- The Hebrew University of Jerusalem- Jerusalem- Israel, The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(7)Shaare Zedek Medical Center- The Hebrew University- Jerusalem Israel, The Juliet Keidan institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;
P776: A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-world Clinical Practice in China: Interim Analysis of Safety resultsECCO'24Year: 2024
Authors: Zheng, C.(1);Chen, B.(2);Yu, J.(3); Wang, X.(4);Li , L.(2);Hu, Y.(5); Xie, L.(5); Liu, M.(6);Chen, M.(2)*;
(1)Shengjing Hospital of China Medical University, Department of Gastroenterology, Shenyang, China;(2)The First Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(3)The First Affiliated Hospital of Shantou University Medical College, Department of Gastroenterology, Guangzhou, China;(4)The Third Xiangya Hospital of Central South University, Department of Gastroenterology, Changsha, China;(5)Takeda China International Trade Co. Ltd, Medical, Shanghai, China;(6)Takeda Development Center Asia, Biostatistics, Beijing, China;
P777: Is the long-term Budesonide use have any influence on Bone Mineral Density in Inflammatory Bowel Diseases?ECCO'24Year: 2024
Authors: Eskazan, T.(1)*;Durcan, E.(2);Bakkaloglu, O.K.(1);Kurt, E.A.(1);Onal, U.(1);Hatemi, İ.(1);Erzin, Y.Z.(1);Celik, A.F.(1);
(1)I.U.C- Cerrahpasa Medical Faculty, Gastroenterology, Istanbul, Turkey;(2)I.U.C. Cerrahpasa Medical Faculty, Endocrinology, Istanbul, Turkey;
P780: Persistence of Health-related Quality of life decline in IBD patients after the COVID-19 outbreakECCO'24Year: 2024
Authors: Herrera De Guise, C.M.(1)*;Mayorga Ayala, L.F.(1);Serra Ruiz, X.(1);Robles Alonso, V.(1);Céspedes Martínez, E.(1);Casellas, F.(1);Pérez Martínez, Z.(1);Oller Jimenez, E.(1);Borruel Sainz, N.(1);
(1)Unitat d@E@Atenció Crohn-Colitis- Hospital Universitari Vall d@E@Hebron, Gastroenterology, Barcelona, Spain;
P781: Mirikizumab administration experience from Ulcerative Colitis patients and healthcare providers: Survey data from the LUCENT clinical programECCO'24Year: 2024
Authors: Clemow, D.(1)*;Radawski, C.(1);Milata, J.(1);Alaka, K.(1);Hunter Gibble, T.(1);Schaum, A.(1);Ezennia, O.(1);Martinez, N.(2);Szaloki, T.(3);Ito, Y.(4);Rodriguez, D.(5);Kirk, K.(5);
(1)Eli Lilly and Company, Eli Lilly and Company, Indianapolis, United States;(2)Gastroenterology Research of America, Gastroenterology Research of America, San Antonio, United States;(3)Javorszky Hospital, Javorszky Hospital, Vac, Hungary;(4)Mito Medical Center, Mito Medical Center, Ibaraki, Japan;(5)Evidera, Evidera, Bethesda, United States;
P782: Comparison of accelerated and standard infliximab induction regimens in Acute Severe Ulcerative Colitis using propensity score: A retrospective multicenter study in a Chinese cohortECCO'24Year: 2024
Authors: Liu, X.(1,2)*;Li, H.(3);Tian, F.(3);Xie, Y.(4);Zhang, X.(4);Zhi, M.(5);Zhang, M.(5);Song, X.(6);Guo, H.(6);Li, X.(7);Liang, J.(7);Shen, J.(8);Li, Y.(1);
(1)Peking Union Medical College Hospital- Peking Union Medical College & Chinese Academy of Medical Science, Department of Gastroenterology, Beijing, China;(2)Peking Union Medical College & Chinese Academy of Medical Science, Eight-year Medical Doctor Program, Beijing, China;(3)Shengjing Hospital of China Medical University, Department of Gastroenterology, Shenyang, China;(4)Nanjing Drum Tower Hospital- School of Medicine- Nanjing University, Department of Gastroenterology, Nanjing, China;(5)the Sixth affiliated hospital- Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(6)Chongqing General Hospital, Department of Gastroenterology, Chongqing, China;(7)Xijing Hospital of Digestive Diseases & State Key Laboratory of Cancer Biology- Fourth Military Medical University, Department of Gastroenterology, Xi@E@an, China;(8)Renji Hospital- School of Medicine- Shanghai Jiao Tong University, Department of Gastroenterology, Shanghai, China;
